Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
11.37
+0.36 (3.27%)
At close: Apr 28, 2026, 4:00 PM EDT
11.37
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:47 PM EDT
Keros Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Keros Therapeutics stock have an average target of 21.86, with a low estimate of 16 and a high estimate of 27. The average target predicts an increase of 92.26% from the current stock price of 11.37.
Analyst Consensus: Buy
* Price targets were last updated on Mar 5, 2026.
Analyst Ratings
The average analyst rating for Keros Therapeutics stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 5 | 5 | 5 | 5 | 3 | 3 |
| Hold | 7 | 7 | 7 | 7 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 15 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $23 → $20 | Buy | Maintains | $23 → $20 | +75.90% | Mar 5, 2026 |
| B of A Securities | B of A Securities | Hold Maintains $18 → $19 | Hold | Maintains | $18 → $19 | +67.11% | Nov 28, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $23 → $27 | Buy | Reiterates | $23 → $27 | +137.47% | Nov 12, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $26 → $23 | Buy | Maintains | $26 → $23 | +102.29% | Nov 11, 2025 |
| Wedbush | Wedbush | Hold Maintains $15 → $16 | Hold | Maintains | $15 → $16 | +40.72% | Nov 6, 2025 |
Financial Forecast
Revenue This Year
340.00K
from 244.06M
Decreased by -99.86%
Revenue Next Year
9.70M
from 340.00K
Increased by 2,751.79%
EPS This Year
-5.24
from 2.30
EPS Next Year
-5.87
from -5.24
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 2.1M | 52.5M | ||||||
| Avg | 339,997 | 9.7M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -99.1% | 15,341.3% | ||||||
| Avg | -99.9% | 2,751.8% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.84 | -2.69 | ||||||
| Avg | -5.24 | -5.87 | ||||||
| Low | -8.84 | -12.29 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.